top of page

Publications

4E3CAF35-902B-4566-9CF3-2FF4F0ED6979_1_100_o.jpeg

Peer-Reviewed Original Research

 

1.     Stoll, S., et al., Seroconversion after COVID-19 vaccination for multiple sclerosis patients on high efficacy disease modifying medications. J. MS and Related Disorders, 2022 Mar 3;60:103719. doi: 10.1016/j.msard.2022.103719. Epub ahead of print. PMID: 35276450; PMCID: PMC8890787.

 

2.     Cree, B. A., Cutter, G., Freedman, M.S., Comi, G…Stoll, S.,et al. “Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomized, double-blind, placebo-controlled, phase 3 trial.” The Lancet. Neurology vol. 19,12 (2020): 988-997. doi:10.1016/S1474-4422(20)30347-1

 

3.     Gmuca, S., D Hardy, S Narula, Stoll S, et al. Validation of Claims-Based Diagnoses of Adult and Pediatric Neuromyelitis Optic Spectrum Disorder and Variations in Diagnostic Evaluation and Treatment Initiation. J. MS and Related Disorders, 2020, 37 101488: 1-5

4.     Stoll, S., T Vartanian, L Rubin, N Rubin, C Litchman. Automated EDSS scoring using a mobile App and Machine Learning.  Neurology, 2020, https://index.mirasmart.com/ AAN2020-002631.html

 5.     Litchman, T., S Stoll. An unusual case of cerebellar ataxia: Does seronegative paraneoplastic disease exist? J. ANNA., 2020, 19:115.

6.     Litchamn, C., S Stoll. CGRP Antagonists: The new headache frontier.  OSP J Neuro Neurological Dis., 2020, 19-1476: 1-6.

 

7.     Stoll, S., and G Rakocevic. Severe acute inflammatory demyelinating -polyradiculoneuropathy with persistent weakness associated with tumor-like nerve root enlargement. J Clin Neuromuscul Dis., 2015, 16(4):220-2.

 

8.     Stoll, S., C Nieves, D Tabby, R Schwartman. Use of therapies other than disease-modifying agents, including complementary and alternative medicine, by patients with multiple sclerosis: A survey study. JAOA., 2012, 112:22-28.

9.     Grunstein, M., and S Stoll. What it's like to be a future neurologist: A Medical Student’s Perspective. Acta Scientific Neurology 2020, 3:20-21.

10.  Stoll S., Rubin, N., Rubin, L., Litchman, T., Keaney, J., Vartanian, T., Litchman, C., Machine learning evaluation of MS patients during the time of COVID. 73rd Annual American Academy of Neurology (AAN) Virtual, USA, 2021.

 

11.  Stratton, C., Bailey, M., Bartels, A., Brenton, N., Odonkor, C., Potter, K., Rumm, H., Smith, D., Stoll, S., Vargas, W., Yeh, A., Zempsky, W., Makhani, N., Guideline for the Assessment and Management of Pain in Childrem with Multiple Sclerosis: A Delphi Panel. 73rd Annual American Academy of Neurology (AAN) Virtual, USA, 2021.

 

12.  S. Hauser, A. Bar-Or, G. Francis, G. Giovannoni, L. Kappos, J. Nicholas, J. Oh, M.P. Sormani, S. Stoll, et al., Examination of fenebrutinib, a highly selective BTKi, on disease progression of multiple sclerosis. 8th Joint ACTRIMS-ECTRIMS Virtual, USA, 2020.

 

13.  S. Hauser, A. Bar-Or, G. Francis, G. Giovannoni, L. Kappos, J. Nicholas, J. Oh, M.P. Sormani, S. Stoll, et al., Rationale and design of two Phase IIIb studies of ocrelizumab at higher dose than the approved dose in patients with RMS and with PPMS 8th Joint ACTRIMS-ECTRIMS Virtual, USA, 2020.

 

14.  Litchman, C., T Vartanian, L Rubin, N Rubin, S Stoll. Automated EDSS scoring using a mobile App & Machine Learning. 72st Annual American Academy of Neurology (AAN), Toronto, Canada, 2020.

 

15.  Isitan, C., E Longbrake, S Stoll, S Wesley. Case Series: Central Nervous System Demyelination in the Setting of Tumor Necrosis Factor-a (TNF- a) Blockers: Uncommon Presentations and Therapeutic Strategies European Conference for Treatment and Research in Multiple Sclerosis (ECTRIMS), Stockholm, Sweden, 2019.

 

16.  Stoll, S., T Litchman, S Wesley, C Litchman. Multiple sclerosis apps: The dawn of a new era: A comprehensive review. 71st Annual American Academy of Neurology (AAN), Philadelphia PA, 2019.

 

17. Rubin, L., M Kruse-Hoyer,C Litchman, S Stoll, D Putrino, S Shetty, C Engel, M Marcille, S Gauthier, J Perumal, N Nealson, U Kaunzner, T Vartanian. Patient Centered Outcomes Analysis for Multiple Sclerosis Using a Mobile Application. 4th Annual American Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), Dallas TX, 2019.

 

18.  Shah, S., S Stoll, T Leist. Plasmapheresis in Corticosteroid-Resistant Acute Disseminated Demyelination: Report of Two Adult Cases. 67 Annual American Academy of Neurology Meeting, Washington DC, MD, 2015.

 

19.  Stoll, S., G Rakoocevic. Immune mediated chronic inflammatory demyelinating            polyneuropathy associated with tumor-like nerve root enlargement mistaken for neurofibromatosis. 62 Annual American Association of Neuromuscular and Electrodiagnostic Medicine, Savannah, GA, 2014.

 

20.  Stoll S., G Rakoocevic. Sub-acute onset of severe chronic inflammatory demyelinating polyradiculoneuropathy weakness associated with tumor-like nerve root involvement: A case report. 66th Annual American Academy of Neurology Meeting, Philadelphia, PA, 2014.

 

21.  Stoll S., D O'Brien, H.I. Chen, M Oddo, E Maloney-Wilenksy,, S Frangos, J Levine, W.A. Kofke, J Faerber, P.D. LeRoux. Intracranial pressure and brain metabolism after severe subarachnoid hemorrhage. 9th Annual Neurocritical Care Society Meeting, Montreal, Canada, 2011.

22.  Stoll S., D O'Brien, H.I. Chen, M Oddo, E Maloney-Wilenksy,, S Frangos, J Levine, W.A. Kofke, Faerber, P.D. LeRoux. The effect of episodes of increased intracranial pressure on brain metabolism. 7th Annual Neurocritical Care Society Meeting, New Orleans, LA, 2009.

bottom of page